MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc. is a clinical development stage pharmaceutical company specializing in therapeutic platforms. Their flagship product, MYMD-1, is a small molecule drug designed to regulate the immune system, targeting chronic inflammation and pro-inflammatory cytokines. Additionally, the company is developing Supera-CBD, a synthetic derivative of cannabidiol for chronic pain, addiction, and epilepsy treatment. With a focus on addressing autoimmune diseases and COVID-19-associated depression, MyMD Pharmaceuticals aims to generate revenue through the commercialization of these innovative drug platforms.